Navigation Links
Synthetic Genomics Inc. Applauds the Venter Institute's Work in Creating the First Synthetic Bacterial Cell
Date:5/20/2010

LA JOLLA, Calif., May 20 /PRNewswire/ -- Synthetic Genomics Inc. (SGI), a privately held company applying synthetic genomic-driven commercial solutions to a variety of global challenges including energy and the environment, applauds the creation of the first synthetic bacterial cell by researchers at the J. Craig Venter Institute (JCVI). SGI has provided nearly $30 million in funding for this work since 2005.

SGI was founded in 2005 by Drs. J. Craig Venter and Hamilton Smith, along with business leaders Juan Enriquez and David Kiernan, to develop commercial applications based on the basic science research of JCVI's synthetic genomics group. The initial business focus of SGI has centered on bioenergy; however the company has now extended its focus to areas of food production, clean water and vaccine development. Many aspects of JCVI's synthetic genomics work have been integrated into the SGI business programs. SGI plans to revolutionize many industrial processes by designing new cells that synthesize the desired commercial products.  

"With the growing impact of climate change, increased global demand for energy, and the potential for environmental impact issues surrounding the drilling for oil and mining for coal, it is clear that new technologies are needed in these areas," said Ari Patrinos, SGI President. "Synthetic genomics research from JCVI and the applied science at SGI have the potential to address these issues."

SGI's alliance with Exxon Mobil Research and Engineering (EMRE) group to create algal biofuels is one example of the important programs at SGI that could benefit from the new tools and technological advances of the synthetic genomics research. This program, announced in July 2009, is a long term research and development alliance focused on finding and optimizing (through synthetic genome techniques and other more traditional metabolic engineering techniques) algae to produce biological crude oil replacements efficiently.

Dr. Venter and the SGI team, as world leaders in developing and driving this area of science, also believe that addressing the societal and ethical issues surrounding synthetic genomics are essential aspects in conducting this research. As such, he and the team have spent equal time focused on these issues in conjunction with and as an augment to the considerable work that has been done at JCVI since 1995. The research at JCVI has undergone significant review at the highest levels of science and government and SGI supports continued review and discussion of this growing area of science. Dr. Venter and the team have met with Congressional members several times since the company's formation to educate them on the field of synthetic genomics.  They have also conducted tours and outreach to state and local governments, have made presentations to many governmental agencies, and speak regularly to other groups (lay audiences, scientific groups, media, etc).

SGI has funded the work at JCVI in exchange for exclusive assignment of intellectual property rights. SGI has filed 13 patent application families on the unique synthetic genomics inventions of the JCVI team. SGI believes that intellectual property is important in the synthetic genomics/biology space as it is one of the best means to ensure that this important area of basic science research will be translated into key commercial products and services for the benefit of society. SGI intends to provide licenses to its synthetic genomics intellectual property.  

About Synthetic Genomics Inc (SGI)

SGI, a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address global energy and environment challenges. The company's main research and business programs include: designing advanced biofuels with superior properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value added products directly from sunlight and carbon dioxide; developing new biological solutions to increase production and/or recovery rates of subsurface hydrocarbons and developing high-yielding, more disease resistant and economic feedstocks. For more information please visit  http://www.syntheticgenomics.com .


'/>"/>
SOURCE Synthetic Genomics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. First Self-Replicating, Synthetic Bacterial Cell Constructed by J. Craig Venter Institute Researchers
2. New SciFinder Features Reveal More Synthetic Pathways and Improve Productivity
3. Industry Forms Association to Address Opportunities and Challenges of Synthetic Biology
4. New Non-Biological Synthetic Replikins(TM) Vaccines Shown to Be Effective and Fast; WorldVaccines(TM), Ltd Formed for Testing and Distribution
5. Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
6. Reportlinker Adds Synthetic Biology: Emerging Global Markets Report
7. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
8. Synthetic Genomics Inc. and ExxonMobil Research and Engineering Company Sign Exclusive, Multi-Year Agreement to Develop Next Generation Biofuels Using Photosynthetic Algae
9. Does Synthetic Biology Need Synthesized Ethics?
10. Synthetic Biology on the Rise
11. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , Mar 23, 2017 Research and ... Global Markets" report to their offering. ... The Global Market ... Billion in 2016 at a CAGR of 8.9%, ... and non-energetic bioproducts into seven major product segments: bio-derived chemicals, ...
(Date:3/23/2017)... March 23, 2017  GlobeImmune, Inc. today announced it ... sale of 12,835,490 shares of its common stock to ... companies. In connection with the sale of its common stock, ... and issue to GlobeImmune 200,000 shares, an estimated $2.0 ... "We are pleased to enter into this strategic ...
(Date:3/23/2017)... 2017 Kineta, Inc., a biotechnology company ... in immuno-oncology, today announced the discovery and characterization ... that activate interferon response factor 3 (IRF3) via ... tumor regression in a murine colon carcinoma mouse ... complete tumor regression to initial drug treatment were ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market ... the next decade to reach approximately $14.21 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
(Date:3/7/2017)... England , March 7, 2017 Brandwatch , ... chosen by The Prince,s Trust to uncover insights to ... across The Trust. The UK,s leading youth charity will ... social campaign results and get a better understanding of the topics ... ...
Breaking Biology News(10 mins):